RFA-TR-25-002 Rare Disease R21 Eligibility Guide
Updated 7 official sources
Quick Answer: RFA-TR-25-002 is an NCATS R21 for rare disease preclinical proof-of-concept studies.
Full answer and how we checked it
It funds efficacy testing in an established model, allows pharmacodynamic and pharmacokinetic work, disallows clinical trials, and caps direct costs at $275,000 over two years. The 2026 decision turns on 7 checks.
Who this is for: Rare disease researchers, translational therapeutics teams, small biotechs, academic drug-discovery groups, animal-model teams, and sponsored-research offices deciding whether a preclinical R21 is enough before IND-enabling work.
Data note: This guide uses NIH RFA-TR-25-002, NIH NOT-TR-26-009, Grants.gov listing 357570, and NIH RePORTER award records checked on October 10, 2026.
In this guide
- October 2026 Source Status
- 7 RFA-TR-25-002 Eligibility Stop Checks
- 5 Source Facts Applicants Should Know
- What NIH Doesn't Tell You
- What NCATS Funded in FY2026
- What Reviewers Weigh and What Gets an Application Pulled
- 6 Evidence Assets That Make This R21 Stronger
- 5 Route Choices Before Drafting
- 6 Bad-Fit Signals
- 21-Day Preclinical Proof Plan
- 7 Above-the-Fold Claims That Need Proof
- 7 Route Checks
- Sources
RFA-TR-25-002 is not a rare disease idea grant. NIH says it funds efficacy studies in an established rare disease preclinical model to show that a proposed therapeutic agent warrants further development. The route is about proof for a therapeutic agent, not building the model from scratch.
Use this guide with the live Rare Disease Preclinical R21 program record. Then compare NIH grants complete guide, NIH R01 R21 R03 K awards comparison, what is a NOFO, Maternal and Pediatric Pharmacology R21 guide, and the Grantsights grant database.
October 2026 Source Status
RFA-TR-25-002 is open for one more round. The original June 2, 2026 due date has passed. On June 5, 2026, NCATS issued NOT-TR-26-009 (opens in a new tab), extending the RFA by one council round: the remaining due date is June 2, 2027 for new and resubmission applications, and the RFA now expires June 3, 2027.
| Current fact | October 10, 2026 applicant read |
|---|---|
| Opportunity number | RFA-TR-25-002 |
| Clinical trial status | Not allowed |
| Remaining due date | June 2, 2027 (5 p.m. local time) |
| Expiration date | June 3, 2027 |
| Budget cap | $275,000 direct costs over 2 years, no more than $200,000 in one year |
| Review timeline for the June 2, 2027 round | Scientific merit review October 2027, advisory council January 2028, earliest start April 2028 |
| Award plan | The RFA's stated set-aside (up to $1.2 million and 3 to 5 awards) was for FY2026; NOT-TR-26-009 doesn't state a separate amount for the extra round |
| Nonresponsive risk | Model development, rare cancer route, no named therapeutic agent, or clinical trial design |
Get grant deadline alerts by email
About once a week, we email a short list of open grant calls with real deadlines from different funders. It isn't limited to the programs in this guide.
No spam. Unsubscribe anytime.
7 RFA-TR-25-002 Eligibility Stop Checks
Within 21 days, use this section as the checkpoint for rare disease preclinical proof before a team commits to the R21 route.
7 stop checks decide whether this route fits.
| Stop check | Strong R21 signal | Red flag |
|---|---|---|
| Rare disease | Fewer than 200,000 people in the U.S. or orphan status evidence | Disease prevalence is not documented |
| Model | Established model is ready now | Proposal asks to develop the model |
| Therapeutic agent | Agent is named and testable | Discovery screen is still open-ended |
| Efficacy | Preclinical efficacy endpoint is defined | Endpoint is only descriptive |
| PK/PD | Pharmacodynamic or pharmacokinetic work supports the proof | Exposure and response are disconnected |
| Trial status | No clinical trial | Human intervention assignment is planned |
| Next step | IND or trial-readiness route is plausible | No development path after award |
If the model is not ready, the route is probably wrong. If the agent is not ready, the route is probably too late-stage for the current team.
5 Source Facts Applicants Should Know
Within 21 days, use this section as the checkpoint for rare disease preclinical proof before a team commits to the R21 route.
5 facts should appear before the applicant commits to drafting.
| Fact | Source-backed read |
|---|---|
| Funding number | RFA-TR-25-002 |
| Mechanism | R21 Exploratory/Developmental Research Grant |
| Clinical trial status | Not allowed |
| Budget | Up to $275,000 direct costs over 2 years |
| Remaining due date | June 2, 2027, with June 3, 2027 expiration |
The RFA says NIH intended up to $1.2 million in FY2026 for 3 to 5 awards, contingent on meritorious applications and funding, and that money went to the first round. The extension notice, NOT-TR-26-009, only adds the June 2, 2027 due date, with merit review in October 2027, council in January 2028, and an earliest start of April 2028. It doesn't set aside a new amount or award count, so an applicant in the remaining round should treat funding as dependent on FY2028 budgets. According to USAspending.gov (opens in a new tab) data, assistance listing 93.350 had about $588.2M in FY2024 obligations across 731 awards active that year.
What NIH Doesn't Tell You
Within 21 days, use this section as the checkpoint for rare disease preclinical proof before a team commits to the R21 route.
4 practical issues decide whether the R21 is worth pursuing.
First, rare disease proof needs prevalence evidence. The application should cite prevalence or orphan status and show why the selected disease belongs here.
Second, the model has to be established. NIH says applications requesting support for development of the rare disease model are not responsive. That means model validation cannot be left for the award.
Third, rare cancers are a bad fit. NIH directs rare cancer applicants to NCI preclinical therapeutics contacts.
Fourth, the R21 should create an investment-grade next step. NIH frames the goal around moving projects toward later investment, IND application development, or clinical-trial progression for repurposing or repositioning.
What NCATS Funded in FY2026
Grantsights checked NIH RePORTER (opens in a new tab) on October 10, 2026 and found 8 FY2026 awards under RFA-TR-25-002, more than the 3 to 5 the RFA anticipated. Every award was made by NCATS, and first-year total costs ran from $415,250 to $462,000. Half were funded on resubmission (A1), so a first-round miss isn't the end of the road.
| Award | Organization | Agent and disease |
|---|---|---|
| 1R21TR006182-01 | UT Southwestern Medical Center | AAV9 gene replacement for PDHA1 deficiency in a mouse model |
| 1R21TR005230-01A1 | Oregon Health & Science University | AAV gene therapy for Alport syndrome in a dog model |
| 1R21TR005505-01A1 | University of Georgia | Repurposed alpelisib for multiple hereditary exostoses |
| 1R21TR005180-01A1 | Children's Mercy Hospital, Kansas City | Everolimus for Vici syndrome |
| 1R21TR006184-01 | University of Minnesota | Nervonic acid for cerebral demyelination in adrenoleukodystrophy |
| 1R21TR006115-01 | Columbia University Health Sciences | Insulin receptor agonists for congenital severe insulin resistance |
The other two went to Stanford and Mount Sinai. Grantsights analysis of the 8 award titles in NIH RePORTER (opens in a new tab) shows each one names a specific agent and, in several cases, the model species. That's the readiness reviewers are asked to judge.
What Reviewers Weigh and What Gets an Application Pulled
According to RFA-TR-25-002 (opens in a new tab), reviewers are asked to evaluate the strength of evidence that the model is relevant to the disease, the biological rationale linking the target to the disease, and whether the agent is ready to be tested for efficacy in vivo or in an advanced in vitro system. The RFA says the approach may not be novel; reviewers judge whether it moves the field toward a therapeutic that's a substantial improvement over, or distinct from, what exists.
Two rules can stop an application before review:
- The Research Strategy must include a paragraph headed "Evidence Supporting Rare Disease Classification" with prevalence references (200,000 or fewer U.S. patients) and FDA orphan status if granted. Leaving it out makes the application non-responsive.
- Foreign subawards aren't allowed. Applications with foreign subawards or subcontracts will be deemed noncompliant, though unfunded collaborations and foreign consultants are still permitted.
6 Evidence Assets That Make This R21 Stronger
Within 21 days, use this section as the checkpoint for rare disease preclinical proof before a team commits to the R21 route.
6 evidence assets make the route stronger. The first is a disease classification memo with prevalence, orphan status if relevant, unmet need, and disease biology.
The second is an established model dossier. Include model type, construct validity, face validity if relevant, prior use, phenotype, reproducibility, and limitations.
The third is a therapeutic-agent summary. Name the agent type, rationale, dose range, delivery route, prior data, manufacturability issues, and safety signals.
The fourth is an efficacy endpoint table. It should separate primary proof endpoints from supportive biomarkers.
The fifth is a PK/PD plan. A rare disease efficacy signal is weaker if exposure and response are not connected.
The sixth is a development path. A team should be able to say what happens after the R21: IND-enabling studies, SBIR/STTR, industry license, R01, or stop.
5 Route Choices Before Drafting
Within 21 days, use this section as the checkpoint for rare disease preclinical proof before a team commits to the R21 route.
5 route choices should be compared.
| Route | Better first read when... | Why |
|---|---|---|
| RFA-TR-25-002 R21 | Established model and therapeutic agent are ready | Route matches proof stage |
| Parent R21 | Rare disease route is closed or not specific enough | Active NIH path may fit |
| SBIR/STTR | Company-led development is central | Product route may fit better |
| NCI preclinical route | Rare cancer is the focus | NIH says rare cancer applicants should seek NCI guidance |
| IND-enabling path | Proof is already strong | R21 may be too early |
Many teams shouldn't draft this R21 until the model and agent are ready.
6 Bad-Fit Signals
Within 21 days, use this section as the checkpoint for rare disease preclinical proof before a team commits to the R21 route.
6 bad-fit signals should be visible early. First, the project does not clearly address a rare disease. Second, the proposal asks to develop the model. Third, the disease is a rare cancer.
Fourth, the therapeutic agent is not ready to test. Fifth, the project includes a clinical trial. Sixth, the R21 result would not support a concrete next development decision.
21-Day Preclinical Proof Plan
Within 21 days, use this section as the checkpoint for rare disease preclinical proof before a team commits to the R21 route.
Days 1 through 3 should confirm source status, due date, clinical-trial status, and budget.
Days 4 through 7 should build the rare disease memo: prevalence, orphan status if relevant, unmet need, disease biology, and target rationale.
Days 8 through 12 should audit the model. If the model is not established, stop and choose another path.
Days 13 through 16 should define the therapeutic-agent proof table: dose, route, timing, endpoints, PK/PD, safety, and failure threshold.
Days 17 through 21 should map the next route. The R21 should produce a go, no-go, license, SBIR/STTR, IND-enabling, or R01 decision.
7 Above-the-Fold Claims That Need Proof
Within 21 days, the first screen should prove 7 claims: what the route funds, whether the source is open or expired, whether clinical trials are allowed, what budget rule applies, who is eligible in practice, what does not fit, and what route should be compared next.
According to NIH in the NOFO (opens in a new tab), this source should be treated as the authority for rules.
7 Route Checks
Added June 2, 2026.
Checked on June 2, 2026 against RFA-TR-25-002 (opens in a new tab), the Grants.gov listing (opens in a new tab), USASpending.gov (opens in a new tab), Grants.gov (opens in a new tab), and USASpending.gov (opens in a new tab).
| Check | Public answer |
|---|---|
| Eligibility | Confirm the applicant, institution, and route rules for RFA-TR-25-002 rare disease preclinical R21 eligibility. |
| Source status | Verify the official listing, notices, due date, and expiration status. |
| Budget | Check award size, cost limits, match, or budget logic when the source provides it. |
| Evidence | Name the data, preliminary work, partner role, or implementation proof needed. |
| Bad fit | Stop if the project belongs in a nearby NIH or federal route. |
| Review criteria | Tie the first page to significance, approach, team, environment, and source-specific criteria. |
| Next action | Decide whether to draft, ask a program contact, or redirect to a nearby route. |
Final public checklist
- Confirm whether R21 is the right route or whether a nearby program fits better.
- Check budget, partner, match, or data-readiness constraints.
Sources
Next steps
Where to go next
These next pages help you move from research into a specific grant choice.
Open rare disease R21 record
Check June 2 2026 due date, June 3 expiration, clinical-trial-not-allowed status, budget cap, and model-readiness risk.
Compare pediatric R21
Use when the project is therapeutic but not a rare disease preclinical proof route.
Compare NIH mechanisms
Check whether R21, R01, SBIR, STTR, or another NIH route fits the next decision.
Find grants that fit you
Free eligibility check: answer 9 questions and see ranked matches with deadlines and fit reasons.
Frequently Asked Questions
What does RFA-TR-25-002 fund?
It funds efficacy studies in an established rare disease preclinical model to show that a therapeutic agent warrants further development.
Are clinical trials allowed?
No. RFA-TR-25-002 is clinical trial not allowed.
What budget applies?
NIH caps direct costs at $275,000 over two years, with no more than $200,000 in any single year.
What is the next deadline?
NIH extended RFA-TR-25-002 under NOT-TR-26-009; the current application due date is June 2, 2027, and the opportunity expires June 3, 2027.
Who should skip this route?
Skip it if the project develops the disease model, targets a rare cancer, lacks a therapeutic agent, or includes a clinical trial.
Last updated October 12, 2026. Corrected October 11, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
PAR-25-369 ELSI R21 eligibility Guide
PAR 25 369 ELSI R21 guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.
maternal pediatric pharmacology R21 eligibility Guide
PAR 25 111 maternal pediatric guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.
PAR-25-357 NEI Secondary Data R21 Eligibility Guide
NIH PAR-25-357 guide: NEI secondary-data R21 eligibility, clinical-trial-not-allowed fit, data readiness, manuscript milestones, and review checks.
PAR-25-266 newborn screening R21 eligibility Guide
PAR 25 266 newborn screening guide: 7 checks for eligibility, source status, budget, evidence, route fit, review criteria, and team readiness in 2026.
PA-25-304: NIH Parent R21 (Clinical Trial Not Allowed)
PA-25-304 is NIH's parent R21 with no clinical trial: $275,000 over 2 years, 21 institutes. Next due Nov 16, 2026 and Feb 16, 2027; expires Jan 8, 2028.
RFA-DA-26-056 Existing Data R21 Eligibility Guide
RFA-DA-26-056 guide: $275,000 R21 for existing substance-use data, no new data collection, December 3, 2026 due date, and 13 funded awards.